Compare ARVN & REAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | REAX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 435.9M |
| IPO Year | 2018 | 2021 |
| Metric | ARVN | REAX |
|---|---|---|
| Price | $8.10 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $15.05 | $5.49 |
| AVG Volume (30 Days) | 685.8K | ★ 4.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $23.04 |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $1.55 |
| 52 Week High | $14.22 | $5.41 |
| Indicator | ARVN | REAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 56.73 |
| Support Level | N/A | $1.59 |
| Resistance Level | $8.90 | $2.30 |
| Average True Range (ATR) | 0.38 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 22.00 | 62.77 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.